Crestwood Advisors Group LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,342 shares of the medical research company’s stock after acquiring an additional 131 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Amgen were worth $583,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Amgen during the first quarter worth about $110,402,000. Swiss National Bank increased its position in shares of Amgen by 26.5% during the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after acquiring an additional 551,600 shares during the last quarter. Bank of Nova Scotia increased its position in shares of Amgen by 414.4% during the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after acquiring an additional 484,868 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Amgen by 37.4% during the first quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock worth $236,775,000 after acquiring an additional 392,538 shares during the last quarter. Finally, Morningstar Investment Services LLC increased its position in shares of Amgen by 283.8% during the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after acquiring an additional 367,894 shares during the last quarter. 78.10% of the stock is currently owned by institutional investors and hedge funds.
AMGN has been the topic of a number of analyst reports. Cann reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 price objective on shares of Amgen in a report on Thursday, September 7th. Deutsche Bank AG initiated coverage on Amgen in a report on Friday, June 23rd. They issued a “hold” rating and a $172.00 price objective for the company. Mizuho reissued a “buy” rating and issued a $198.00 price objective (up from $183.00) on shares of Amgen in a report on Thursday, September 28th. Finally, William Blair reissued a “market perform” rating on shares of Amgen in a report on Monday, June 26th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. Amgen has a consensus rating of “Buy” and a consensus price target of $189.99.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.19% of the company’s stock.
Shares of Amgen Inc. (AMGN) opened at 182.76 on Friday. The firm’s 50-day moving average is $183.15 and its 200 day moving average is $170.75. The firm has a market capitalization of $133.36 billion, a P/E ratio of 16.65 and a beta of 1.36. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the business posted $2.84 earnings per share. Equities research analysts forecast that Amgen Inc. will post $12.58 EPS for the current fiscal year.
WARNING: “Crestwood Advisors Group LLC Has $583,000 Stake in Amgen Inc. (AMGN)” was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/10/13/crestwood-advisors-group-llc-has-583000-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.